Relmada Therapeutics Inc
Relmada Therapeutics Inc (RLMD) Covered Calls
As of September 18, 2026, RLMD has 4 covered call opportunities in the coming three months. Return ranges from 25.0 to 88.1% until expiration. Annualized return ranges from 53.5 to 200.2%. The nearest expiration is November 20, 2026. Maximum potential profit is $363.
Read more
Running RLMD covered calls helps you generate consistent income from Relmada Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Relmada Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best RLMD covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if RLMD stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling RLMD covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Relmada Therapeutics Inc covered call is worth writing.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Income-focused investors, long-term RLMD holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling RLMD covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Relmada Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile55.16% Neutral
- Market cap (M$)439
- 52 weeks high-48.50%
- 52 weeks low180.27%
- Analyst recommendationStrong Buy
1.00 - Target price$10.75
203.25% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.93
- EPS growth next 5 years20.09%
As of September 18, 2026
| 2027-02-19 | 154 | 7.50 | 82.04 | 0.10 | 0.40 | 348.00 | 84.47 | 200.20 | -2.43 | +0.23 | 547 | 0.30 |
| 2026-11-20 | 63 | 5.00 | 21.36 | 0.15 | 0.40 | 103.00 | 25.00 | 144.84 | -3.64 | +0.35 | 217 | 0.25 |
| 2027-05-21 | 245 | 7.50 | 82.04 | 0.25 | 0.50 | 363.00 | 88.11 | 131.26 | -6.07 | +0.30 | 0 | 0.25 |
| 2027-05-21 | 245 | 5.00 | 21.36 | 0.60 | 1.30 | 148.00 | 35.92 | 53.52 | -14.56 | +0.56 | 0 | 0.70 |
As of September 18, 2026
Sell covered calls with the data behind you
Find the best RLMD covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→